Provided by Tiger Fintech (Singapore) Pte. Ltd.

I-MAB

5.77
-0.7900-12.04%
Post-market: 5.74-0.0300-0.52%19:55 EDT
Volume:4.10M
Turnover:23.13M
Market Cap:665.09M
PE:-11.77
High:6.39
Open:6.30
Low:4.85
Close:6.56
52wk High:6.79
52wk Low:0.5950
Shares:115.27M
Float Shares:48.23M
Volume Ratio:1.58
T/O Rate:8.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4902
EPS(LYR):-0.2738
ROE:-18.46%
ROA:-10.36%
PB:3.38
PE(LYR):-21.07

Loading ...

I-Mab Is Maintained at Buy by BTIG

Dow Jones
·
6 hours ago

I-Mab to Rebrand as NovaBridge Biosciences, Eyes Hong Kong IPO

MT Newswires Live
·
Yesterday

I-Mab - Kyler Lei Appointed as CFO of I-Mab

THOMSON REUTERS
·
Yesterday

Press Release: I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

Dow Jones
·
Yesterday

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

GlobeNewswire
·
Oct 14

BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

TIPRANKS
·
Oct 14

Leerink Partners Initiates Coverage on I-MAB With Outperform Rating, $9 Price Target

MT Newswires Live
·
Oct 03

I-Mab Initiated at Outperform by Leerink Partners

Dow Jones
·
Oct 03

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

TIPRANKS
·
Oct 03

I-Mab initiated with an Outperform at Leerink

TIPRANKS
·
Oct 03

BUZZ-I-Mab tumbles on China drug report, analyst calls selloff overreaction

Reuters
·
Sep 11

BTIG says buy I-Mab amid ‘misperceived’ China risk

TIPRANKS
·
Sep 11

I-Mab Price Target Maintained With a $7.00/Share by BTIG

Dow Jones
·
Sep 11

BTIG Initiates I-MAB at Buy With $7 Price Target

MT Newswires Live
·
Sep 09

I-Mab Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
Sep 08

BRIEF-I-Mab Announces Acceleration Of Givastomig Investment And Leadership Appointments

Reuters
·
Sep 08

BRIEF-I-Mab Wei Fu, I-Mab’S Chairman Of Board, Appointed As Executive Chairman

Reuters
·
Sep 08

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

THOMSON REUTERS
·
Sep 08

I-Mab: Plans Global Phase 2 Study for Givastomig in Q1 2026

THOMSON REUTERS
·
Sep 08

I-Mab: Wei Fu, I-Mab’s Chairman of Board, Appointed as Executive Chairman

THOMSON REUTERS
·
Sep 08